By Joe Hoppe
Scancell Holdings PLC said Wednesday that it swung to a pretax loss for the first half of fiscal 2023, and that net assets fell.
The London-listed biopharmaceutical company posted a pretax loss for the six months ended Oct. 31 of 4.1 million pounds ($5.1 million), from a pretax profit of GBP2.5 million a year prior. This reflects…
Read the full article here